In France, although set regulations defined classes of patients for whom GnRH antagonists were prescribed, the decisions were steered mostly by the physicians who may have included PCa men with all T\stages with nodal involvement and metastatic disease 47

In France, although set regulations defined classes of patients for whom GnRH antagonists were prescribed, the decisions were steered mostly by the physicians who may have included PCa men with all T\stages with nodal involvement and metastatic disease 47. in the UK, Scotland, Belgium, the Netherlands and France. Data from five countries improved the study power and internal validity required to compare risk of CVD between GnRH agonists and AZD8186 antagonists, the latter being a fairly new drug with limited data in individual countries. which are extracted from general practices (GP) in the UK using the VISION 28 system. The data are coded using standardized codes called the readcodes 29 or medcodes and drugcodes. As some individuals may be present in both THIN and National Health Support (NHS) Scotland databases, PCa men from Scotland were excluded from THIN. The study period used for this project extended from 2010 to 2016. Open in a separate window Physique 1 Business of data in the THIN database. National health support Scotland Data were linked from five databases in Scotland 30: the Scottish Cancer Registry, the Scottish National Prescribing Information System (PIS), the General or Acute Inpatient and Day Case AZD8186 dataset (SMR01), the Outpatient Attendance dataset (SMR00) and the National Records of Scotland AZD8186 Death Records (NRSDR) using the unique identifier number, Community Health Index Number. The resulting dataset captures information on PCa diagnosis and treatment (from the Scottish Cancer Registry), community prescriptions in Scotland (PIS), hospital diagnoses and operations (SMR01), diagnoses and procedures from outpatient clinics (SMR00) and the date and Rabbit Polyclonal to ATG4D cause of death (NRSDR) 30. Men diagnosed with PCa from 2010 to 2015 with follow\up until 2017 were part of this study. Belgian cancer registry All new cancer cases are legally required to be registered in Belgium in the Belgian Cancer Registry (BCR) 31. The database constitutes of populace\based clinicalCpathological information on new malignancy diagnoses with almost complete coverage of the Belgian populace since 2004. Administrative data on reimbursed medical acts and dispensed in\ and outpatient medications are provided to the BCR by the health insurance companies (HIC), covering a period from 1 year before until 5 years after the date of cancer diagnosis 32. The HIC data contain information regarding the date and type of charged diagnostic and therapeutic procedures, and regarding the date, amount and dosages of dispensed medications. Following specific authorizations, hospital discharge data (HDD) covering hospitalizations of the patients registered by BCR from the year prior to the incidence date onwards are made available using specific codes 33. These records contain information on hospital admission and discharge dates, diagnoses and procedures for each hospitalization. Both HIC and HDD data are deterministically coupled to the BCR database, using the national social security number as a unique patient identifier. Cause of death information for all those Belgian inhabitants is usually provided by the three different Belgian regions and probabilistically coupled to the BCR data (coupling percentage 98%). The current project used data from 2010 to 2013. PHARMO Database Network The PHARMO Database Network is usually a populace\based network of healthcare databases combining data from both primary and secondary healthcare settings in the Netherlands 34. These different data sources, including data from GPs, in\ and outpatient pharmacies, clinical laboratories, hospitals, the cancer registry, pathology registry and perinatal registry, are linked on a patient level through validated algorithms. Detailed information around the methodology and the validation of the used record linkage method can be found elsewhere 35. For this study, data from the Out\patient Pharmacy Database, Hospitalisation Database and Cancer Registry were used. The Out\patient Pharmacy Database includes detailed information on GP or specialist prescribed healthcare products dispensed by outpatient pharmacies. The dispensing records include information on type of product, date, strength and dosage regimen, quantity, route of administration, prescriber specialty and costs. The Hospitalisation Database comprises of hospital admissions for more than 24 hours and admissions for less than 24 hours, for which a bed was required (i.e. inpatient records) from the Dutch Hospital Data Foundation. The records include information on hospital admission and discharge dates, discharge diagnoses and procedures. The Cancer Registry comprises information on newly diagnosed cancer patients in the Netherlands 34. For the current project, we used data from 2010 to 2015. French Health National Database (SNIIRAM) The French Health National Database based on claims data called the Systme National AZD8186 d’Informations Inter\Rgimes de l’Assurance Maladie (SNIIRAM) was used for this study 36. SNIIRAM combines.